**University of Vermont Cancer Center (UVMCC)**

The University of Vermont Cancer Center is an academic cancer center representing a partnership between the University of Vermont and University of Vermont Medical Center. Founded in 1974, it is the only such cancer center in the entirety of Vermont, and in the upstate New York region, providing cutting-edge cancer care, advancing cancer research, and educating the next generation of cancer scientists and health care professionals. The UVM Cancer Center works to reduce the burden of cancer in its community and throughout the world, providing important infrastructure, expertise, and resources to facilitate collaborative and innovative research, cancer care, and education. There are more than 200 members of the Cancer Center who conduct rigorous basic, clinical, translational and population research as well as community outreach, education, survivorship, prevention, and screening programming.

The UVM Cancer Center provides leadership to a unique catchment area, including 14 community hospitals that provide health care to cancer patients in a regional health care network. The UVM Cancer Center also takes primary responsibility for outreach, public education, and physician education related to cancer for UVM.

The physical space of the UVM Cancer Center represents 16,500 square feet of research laboratory space, including several of the laboratory-focused shared resources, in the Health Sciences Research Complex and Given buildings of the UVM Larner College of Medicine. The Cancer Center’s administrative offices, including support staff, Director’s and Associate Director’s offices, conference rooms, and data management core facility,, are also located in the Health Sciences Research Facility. The Clinical Trials Office holds 2,200 in the Courtyard building of the Larner College of Medicine, as well as dedicated research space in the oncology clinic at the UVM Medical Center.

*Research coordination* is provided by research nurses and research coordinators to help in the conduct of enrolling, treating, and follow-up of subjects enrolled on clinical studies under Good Clinical Practice guidelines. Research nurses and research coordinators support Transdisciplinary Teams to ensure better streamlining and accountability of the clinical research activities. Activities include maintaining the status and list of clinical trials; screening patients for trial participation; helping with consenting patients; scheduling all required events per protocols; maintaining an accurate list of adverse events and outcomes of patients enrolled in clinical trials; data entry in CRFs; relations with monitors and auditors; collaborating with the regulatory coordinators to maintain regulatory compliance; and collaborating with the Cancer Translational Research Laboratory (CTRL) when obtaining tissue samples.

*Quality Assurance:*The UVMCC is committed to assuring that research is conducted according to the highest scientific, ethical and Good Clinical Practice standards and complies with regulatory guidelines for all industry, research grant, and/or NCI programs. To that end, nine protocols were developed in 2016 designed to specifically address quality assurance and maintenance of GCP standards. The UVMCC has taken advantage of the UVM IRB move to the Collaborative Institutional Training Initiative (CITI) platform to enhance investigator knowledge and further promote GCP. Standard quality assurance measures include an initial orientation that provides training to new faculty and staff, and on-going clinical trial education is available through a weekly staff meeting and various internal and external tutorials. Auditing involves both internal and external audit preparations. Internal auditing involves a retrospective review of institutional and NCI trials and compliance to protocol and good clinical practices. External auditing includes preparing for NCI NCTN audits. NCI Program Quality Assurance tracks adherence to requirements of the NCI sponsored trials. The UVMCC also undertook an extensive self-audit in the last 6 months to further ensure the highest quality of research conduct. As part of this extensive audit process, accruals were held until the successful completion of audit. 58 of 65 clinical trials have reopened.